Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
- PMID: 27099466
- PMCID: PMC4821382
- DOI: 10.2147/OPTH.S98607
Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
Abstract
Objective: Fixed combination glaucoma medication is increasingly used in glaucoma treatment. There is a lack of comparative study in the literature of non-beta blocker combination agents used adjunctively with a glaucoma agent in a different class. The objective of this study is to evaluate the effect of intraocular pressure (IOP) control and tolerability of non-beta blocker combination suspension with prostaglandin analogs (PGA) in patients with open angle glaucoma who were previously treated with beta blocker combination solution with PGA.
Design: Open-label retrospective review of patient records.
Patients and methods: This study looked at patients with open angle glaucoma taking dorzolamide/timolol solution with PGA that were switched to brinzolamide/brimonidine combination suspension with PGA. This study reviewed the charts of all patients who were at least 21 years old with a clinical diagnosis of open-angle glaucoma or ocular hypertension in at least one eye. Patients needed to have been treated with concomitant use of PGA and dorzolamide/timolol solution for at least one month. Patients using dorzolamide/timolol solution plus PGA with medication related ocular irritation were switched to brinzolamide/brimonidine suspension with the same PGA. Best-corrected visual acuity, ocular hyperemia grading, slit lamp biomicroscopy and Goldmann applanation tonometry measurements, and patient medication preferences were assessed at baseline, 1 month and 3 months.
Results: Forty eyes with open angle glaucoma. The mean age of the patients was 68 and 60% were females. The IOP before the switch was 17.2 and 16.5 (P=0.70) following the switch at 3 months. We found a decreasing trend of ocular hyperemia (P=0.064) and strong preference (P=0.011) for non-beta blocker combination suspension but no difference of visual acuity and slit lamp findings.
Conclusion: Brinzolamide/brimonidine combination suspension when used adjunctively with PGA is equally effective. Patients in this study reported greatly reduced ocular redness and shorter duration of stinging with non-beta blocker combination suspension. Their preference of it over dorzolamide/timolol combination solution makes it a viable treatment option, particularly for the aging glaucoma patient with comorbidities that restrict the beta blocker use.
Keywords: Open angle glaucoma; brimonidine; brinzolamide; dorzolamide; prostaglandin analogs; side effects; timolol.
Similar articles
-
Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.Ophthalmology. 2009 Sep;116(9):1719-24. doi: 10.1016/j.ophtha.2009.03.050. Epub 2009 Jul 9. Ophthalmology. 2009. PMID: 19592108 Clinical Trial.
-
Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.Curr Med Res Opin. 2009 Jul;25(7):1645-53. doi: 10.1185/03007990902994041. Curr Med Res Opin. 2009. PMID: 19476406 Clinical Trial.
-
Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.J Ocul Pharmacol Ther. 2009 Dec;25(6):541-4. doi: 10.1089/jop.2009.0045. J Ocul Pharmacol Ther. 2009. PMID: 20028261 Clinical Trial.
-
Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis.Front Pharmacol. 2019 Jun 25;10:679. doi: 10.3389/fphar.2019.00679. eCollection 2019. Front Pharmacol. 2019. PMID: 31293419 Free PMC article.
-
Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension.Drugs Aging. 2003;20(12):919-47. doi: 10.2165/00002512-200320120-00008. Drugs Aging. 2003. PMID: 14565787 Review.
Cited by
-
Topical brimonidine for pyogenic granuloma after paronychia surgery.JAAD Case Rep. 2020 Nov 9;7:41-43. doi: 10.1016/j.jdcr.2020.11.004. eCollection 2021 Jan. JAAD Case Rep. 2020. PMID: 33319002 Free PMC article. No abstract available.
-
Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre.Int Ophthalmol. 2020 Feb;40(2):377-383. doi: 10.1007/s10792-019-01194-6. Epub 2019 Oct 24. Int Ophthalmol. 2020. PMID: 31650353
References
-
- Collaborative Normal-Tension Glaucoma Study Group Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4):487–497. - PubMed
-
- The AIG Investigators The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429–440. - PubMed
-
- Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. - PubMed
-
- Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48–56. - PubMed
-
- McCarty CA, Mukesh BN, Kitchner TE, et al. Intraocular pressure response to medication in clinical setting: the Marshfield Clinic Personalized Medicine Research Project. J Glaucoma. 2008;17(5):372–377. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources